健康科学ジャーナル

  • ISSN: 1108-7366
  • ジャーナル h-index: 51
  • 雑誌引用スコア: 10.69
  • ジャーナルのインパクトファクター: 9.13
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • シナール完了
  • シマゴ
  • 電子ジャーナルライブラリ
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • EMケア
  • OCLC-WorldCat
  • 大学補助金委員会
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

Health Results and Tuberculosis Drugs in Nations with National Essential Medicines List

Robert Busen*, Frances Klsey

Tuberculosis (TB) is a major global health issue, requiring access to effective and affordable medicines for successful treatment. The presence of a National Essential Medicines List (NEML) plays a crucial role in ensuring access to TB medicines and improving health outcomes. This article examines the impact of NEMLs on TB medicines and health outcomes in countries. NEMLs enhance access to TB medicines, promote quality assurance and standardization, improve affordability, and positively influence health outcomes related to TB. The inclusion of essential TB medicines on NEMLs facilitates equitable access, reduces treatment costs, and contributes to better patient outcomes, including increased treatment success rates and reduced mortality. NEMLs are essential in the global fight against tuberculosis and should be prioritized by governments and healthcare authorities to achieve improved health outcomes and control the spread of TB.